Senseonics Holdings, Inc. logo

Senseonics Holdings, Inc. (SENS)

Market Open
8 Dec, 16:41
AMEX AMEX
$
6. 67
+0.05
+0.83%
$
252.46M Market Cap
- P/E Ratio
0% Div Yield
615 Volume
-0.12 Eps
$ 6.62
Previous Close
Day Range
6.55 6.74
Year Range
5.14 28
Want to track SENS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 80 days
Senseonics Holdings (SENS) Reports Q4 Loss

Senseonics Holdings (SENS) Reports Q4 Loss

Senseonics Holdings (SENS) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.03 per share a year ago.

Zacks | 9 months ago
Senseonics Holdings (SENS) Reports Q3 Loss, Tops Revenue Estimates

Senseonics Holdings (SENS) Reports Q3 Loss, Tops Revenue Estimates

Senseonics Holdings (SENS) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.04 per share a year ago.

Zacks | 1 year ago
Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript

Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript

Senseonics Holdings, Inc. (NYSE:SENS ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Tim Goodnow - President and Chief Executive Officer Rick Sullivan - Chief Financial Officer Brian Hansen - President of CGM at Ascensia Diabetes Care Conference Call Participants Brian Langan - Morgan Stanley Vernon Bernardino - H.C. Wainwright Operator Good day, everyone, and welcome to the Senseonics Third Quarter 2024 Earnings Call.

Seekingalpha | 1 year ago
Senseonics Stock Down Despite New FDA Approval for Eversense 365

Senseonics Stock Down Despite New FDA Approval for Eversense 365

SENS' latest regulatory clearance is likely to simplify diabetes management with the help of a long-lasting CGM system.

Zacks | 1 year ago